利拉鲁肽治疗2型糖尿病患者应答的影响因素分析

Analysis of influencing factors for therapeutic response of liraglutide in the treatment of patients with type 2 diabetes mellitus

目的 分析利拉鲁肽治疗2型糖尿病(T2DM)患者应答的影响因素。方法 T2DM患者102例采用利拉鲁肽治疗6个月后分为两组:治疗应答组73例,HbAlc降低≥1%或HbAlc<7%;治疗不应答组29例。分析两组患者临床资料,采用logistic回归分析利拉鲁肽治疗应答的影响因素。结果 应答组糖尿病病程短于不应答组(P<0.01)。与治疗前比较,治疗6个月应答组体重、BMI以及HbA1c、FBG、TC、TG和LDL-C水平均降低,胰岛β细胞功能指数以及HDL-C和SCr水平升高(P<0.05),不应答组体重和BMI降低,HbA1c和FBG水平升高(P<0.05)。治疗前HbAlc水平较高是利拉鲁肽治疗应答的保护因素,糖尿病病程较长是利拉鲁肽治疗应答的危险因素(P<0.05)。结论 糖尿病病程和治疗前HbA1c水平是利拉鲁肽治疗T2DM患者应答的影响因素。

Objective To analyze the influencing factors for the therapeutic response of liraglutide in the treatment of the patients with type 2 diabetes mellitus(T2DM).Methods A total of 102 T2DM patients were treated with liraglutide for 6 months,of whom 73 cases(group A)were with the HbAlc level decrease by≥1%or HbAlc<7%,which was decreased by<1%or HbA1c≥7%in 29 cases(group B).The clinical data of the two groups were analyzed,and the influencing factors for the therapeutic response of liraglutide were analyzed by logistic regression.Results The duration of diabetes was shorter in group A than that in group B(P<0.01).Compared with before,the body weight,BMI and levels of HbAlc,FBG,TC,TG and LDL-C were decreased,and homeostatic model assessment ofβ-cell function and levels of HDL-C and SCr were increased 6 months after treatment in group A(P<0.05).Compared with before,body weight and BMI were decreased,while levels of HbAlc and FBG were increased 6 months after treatment in group B(P<0.05).Higher HbAlc level before treatment was the protective factor for the therapeutic response of liraglutide,and longer duration of diabetes was the risk factor(P<0.05).Conclusion The duration of diabetes and HbAlc level before treatment are the influencing factors for the therapeutic response of liraglutide in T2DM patients.